Page 22 - Delaware Medical Journal - January/February 2021
P. 22
This study displayed an average decrease in opioid use of 31.3%
use could serve as a useful adjunct treatment to reduce opioid use among chronic pain patients.
CONCLUSION
According to the CDC’s “2018 Annual Surveillance Report
of Drug-Related Risks and Outcomes,” Delaware ranked the highest in the prescription of opioids over 90 MME and for the most long-acting/extended-release opioids in the United States
in 2017 and in 2018.9,10 While the rates of opioid prescriptions have been decreased across the country and in Delaware over the last decade, Delaware still ranks among the highest in several opioid-related statistics and in opioid-related overdose deaths, displaying that any tool or treatment, such as medical cannabis, that can help reduce the use of opioids among Delawareans
Do we have your
updated information?
Please be sure to inform us of any changes to
Medical Society of Delaware staff works hard
to ensure we have the most up-to-date contact information for our members, but we need your help! Please be sure to report any changes of address, email updates, change of practice, or any other change that we should update in our system.
Please contact Michelle Seymour, Membership Coordinator
at Michelle.Seymour@MedSocDel.org or (302) 224-4905 with any new information you need to share.
CONTRIBUTORS
■ ALAN G. BALU is student at Georgetown University, class of 2021, studying Biochemistry and Computer Science, with acceptance to Georgetown University School of Medicine. He also conducts research in the Dzakpasu lab at Georgetown, studying the synchronization of neural networks using MEA systems.
■ ALEX L. WOODS, MD, MPH is a physician at NYU. He earned his MPH from Harvard T. H. Chan School of Public Health and his MD from Geisel School of Medicine at Dartmouth.
■ JAHAN MARCU, PHD has over 15 years of experience in cannabinoid research, policy, and operations. He has been a passionate advocate focused on consumer safety and the therapeutic benefits of cannabis- based medicine. He is also among a select group of professionals globally who have earned a PhD focused on the endocannabinoid system.
■ GANESH R. BALU, MD is board certified in Physical, Medical, and Rehabilitation and Pain Medicine. He has offered comprehensive and integrative chronic pain management programs in multiple Delaware locations for the past 20 years, including medical cannabis.
Operators standing by!
22
Del Med J | January/February 2021 | Vol. 93 | No. 1
